<DOC>
	<DOCNO>NCT01656265</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ARQ 197 hepatocellular carcinoma ( HCC ) patient treat daily oral ARQ 197 , determine recommend dose ARQ 197 advance HCC patient .</brief_summary>
	<brief_title>Study ARQ 197 Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Confirmed HCC patient resistant , intolerable , reject systemic sorafenib therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ChildPugh classification A time registration Adequate bone marrow , liver , renal function within 14 day prior registration Prior therapy cMet inhibitor ( include ARQ 197 ) Any systemic antitumor treatment investigational agent within 2 week prior registration . If treatment/agent antibody , within 4 week Local treatment malignancy within 4 week prior registration Major surgical procedure within 4 week prior registration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>